PDF(Pubmed)
Abstract：
OBJECTIVE: Refugees are at higher risk for hepatitis B (HBV) and hepatitis C (HCV), but often face unique healthcare barriers to vaccination, testing, and treatment. This scoping review aimed to identify and characterize HBV and HCV prevention and care services serving refugee populations globally.
METHODS: A literature search was conducted on Embase, Cochrane, and PubMed databases. Research studies published in English between January 2010 to July 2022 describing an HBV or HCV prevention, testing, or treatment intervention for refugees were included.
RESULTS: There were a total of 69 articles reporting viral hepatitis prevalence, implementation of services, or economic modelling. Of the 38 implementation studies, 14 were stand-alone HBV and/or HCV interventions, while 24 studies included HBV and/or HCV in an intervention targeting multiple infectious diseases and/or parasitic infections. Interventions commonly included a testing (n = 30) or referral (n = 24) component. Frequently reported features to promote program accessibility included bilingual services (n = 25), community partnerships (n = 21), and multidisciplinary staff members (n = 18), such as cultural and/or linguistic mediators, community health workers, community health leaders, lay health workers, local health staff, members of the refugee community, and social workers. The most commonly reported challenge was the transience of refugees (n = 5). Twenty studies noted funding sources, of which twelve reported governmental funding (not including national health insurance) and eight reported that refugees received national health insurance.
CONCLUSIONS: This is the first scoping review to characterize the types of hepatitis prevention, screening, and treatment interventions serving refugee populations globally. Published experiences of HBV and HCV services for refugee populations remain limited. Additional efforts are needed to disseminate models of hepatitis interventions for refugees to ensure access to care for this key population. To achieve hepatitis elimination globally, best practices must be identified and shared to expand access to hepatitis services for refugee populations.
METHODS: A literature search was conducted on Embase, Cochrane, and PubMed databases. Research studies published in English between January 2010 to July 2022 describing an HBV or HCV prevention, testing, or treatment intervention for refugees were included.
RESULTS: There were a total of 69 articles reporting viral hepatitis prevalence, implementation of services, or economic modelling. Of the 38 implementation studies, 14 were stand-alone HBV and/or HCV interventions, while 24 studies included HBV and/or HCV in an intervention targeting multiple infectious diseases and/or parasitic infections. Interventions commonly included a testing (n = 30) or referral (n = 24) component. Frequently reported features to promote program accessibility included bilingual services (n = 25), community partnerships (n = 21), and multidisciplinary staff members (n = 18), such as cultural and/or linguistic mediators, community health workers, community health leaders, lay health workers, local health staff, members of the refugee community, and social workers. The most commonly reported challenge was the transience of refugees (n = 5). Twenty studies noted funding sources, of which twelve reported governmental funding (not including national health insurance) and eight reported that refugees received national health insurance.
CONCLUSIONS: This is the first scoping review to characterize the types of hepatitis prevention, screening, and treatment interventions serving refugee populations globally. Published experiences of HBV and HCV services for refugee populations remain limited. Additional efforts are needed to disseminate models of hepatitis interventions for refugees to ensure access to care for this key population. To achieve hepatitis elimination globally, best practices must be identified and shared to expand access to hepatitis services for refugee populations.
摘要：
目的：难民有较高的乙型肝炎（HBV）和丙型肝炎（HCV）的风险，但经常面临疫苗接种的独特医疗障碍，测试,和治疗。本范围审查旨在确定和表征服务于全球难民人口的HBV和HCV预防和护理服务。
方法：在Embase上进行了文献检索，科克伦,和PubMed数据库。2010年1月至2022年7月以英语发表的研究研究描述了HBV或HCV预防，测试,或包括对难民的治疗干预。
结果：共有69篇报告病毒性肝炎患病率，实施服务，或经济模型。在38项实施研究中，14是独立的HBV和/或HCV干预，而24项研究将HBV和/或HCV纳入针对多种感染性疾病和/或寄生虫感染的干预措施。干预通常包括测试（n=30）或转诊（n=24）组件。经常报告的促进节目可访问性的功能包括双语服务(n=25)，社区伙伴关系(n=21)，和多学科工作人员(n=18)，如文化和/或语言中介，社区卫生工作者,社区卫生领导,非专业卫生工作者，当地卫生人员,难民社区的成员，和社会工作者。最常报告的挑战是难民的短暂性（n=5）。20项研究指出了资金来源，其中12个报告了政府资金(不包括国家健康保险)，8个报告说难民获得了国家健康保险。
结论：这是首次对肝炎预防类型进行范围审查，筛选,以及为全球难民人口服务的治疗干预措施。为难民人口提供HBV和HCV服务的公开经验仍然有限。需要进一步努力传播针对难民的肝炎干预模式，以确保这一关键人群获得护理。为了实现全球消除肝炎，必须确定和分享最佳做法，以扩大难民人口获得肝炎服务的机会。
方法：在Embase上进行了文献检索，科克伦,和PubMed数据库。2010年1月至2022年7月以英语发表的研究研究描述了HBV或HCV预防，测试,或包括对难民的治疗干预。
结果：共有69篇报告病毒性肝炎患病率，实施服务，或经济模型。在38项实施研究中，14是独立的HBV和/或HCV干预，而24项研究将HBV和/或HCV纳入针对多种感染性疾病和/或寄生虫感染的干预措施。干预通常包括测试（n=30）或转诊（n=24）组件。经常报告的促进节目可访问性的功能包括双语服务(n=25)，社区伙伴关系(n=21)，和多学科工作人员(n=18)，如文化和/或语言中介，社区卫生工作者,社区卫生领导,非专业卫生工作者，当地卫生人员,难民社区的成员，和社会工作者。最常报告的挑战是难民的短暂性（n=5）。20项研究指出了资金来源，其中12个报告了政府资金(不包括国家健康保险)，8个报告说难民获得了国家健康保险。
结论：这是首次对肝炎预防类型进行范围审查，筛选,以及为全球难民人口服务的治疗干预措施。为难民人口提供HBV和HCV服务的公开经验仍然有限。需要进一步努力传播针对难民的肝炎干预模式，以确保这一关键人群获得护理。为了实现全球消除肝炎，必须确定和分享最佳做法，以扩大难民人口获得肝炎服务的机会。
